CTN Bulletin logo
November 17, 2023  

Funding Opportunities from NIDA

Blocks spelling out the word FUNDINGRFA-DA-24-036The Rural Community-Centered Drug Misuse Prevention and Harm Reduction Research: Addressing Implementation, Dissemination, and Equity Challenges across the Continuum of Care (R61/R33 Clinical Trial Only)

This notice of funding opportunity (NOFO) will support research projects that develop and test drug misuse prevention and/or harm reduction strategies, extending the continuum of care within U.S. rural communities impacted by the opioid/stimulant epidemic. The overall goal is to reduce drug use and associated risks and harms for individuals with unmet prevention and/or harm reduction needs. Research activities will be conducted in two phases (i.e., developmental R61 phase and implementation and effectiveness trial R33 phase). Each phase of the project must involve community partners and potential end users of the research findings. These projects should yield effective community-level strategies to meet prevention and/or harm-reduction needs in diverse rural communities in the U.S. Applications are due January 26, 2024.

PAR-23-270: Screening, Brief Intervention and Referral to Treatment or Prevention for Alcohol, Tobacco, and Other Drugs Use and Misuse in Adult Populations that Experience Health Disparities

Help enhance Screening, Brief Intervention and Referral to Treatment (SBIRT) with referral to preventive intervention approaches for populations that experience health disparities! The National Institutes of Health (NIH) Office of Disease Prevention (ODP) and participating Institutes, Centers, and Offices are inviting applications for research projects that test innovative approaches to implementing Screening, Brief Intervention and Referral to Treatment or Prevention (SBIRT/P) for alcohol, tobacco, and other drugs (ATOD) use and misuse in adult populations that experience health disparities.

This R01 funding opportunity will support clinical trial research that develops and prospectively tests implementation strategies that overcome barriers to SBIRT/P in diverse settings. Projects are strongly encouraged to include robust engagement with relevant health care and community partners and examine organizational and system contexts. First receipt date is February 5, 2024.

CTN snowflake logoAND HOT OFF THE PRESS:

The National Drug Abuse Treatment Clinical Trials Network (UG1 Clinical Trial Required) NOFO has now been published! Check it out here: RFA-DA-25-027: The National Drug Abuse Treatment Clinical Trials Network (UG1 Clinical Trial Required) (nih.gov)

· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·

CTN Protocol Template v6.0 Now Available in the Investigator’s Toolbox 

The Clinical Coordinating (CCC) and Data and Statistics (DSC) Centers at Emmes have completed upversioning of the CTN Protocol Template from v5.0 to v6.0, and v6.0 is now available in the CTN Toolbox under "Protocol Development."

There were substantial revisions made in this upversioning that are documented in a separate Summary of Changes document, which is also available in the CTN Toolbox. Key changes include clarification of the Sponsor role and NIDA’s role as funder in CTN studies, addition of a section to describe Screen Failures, reorganization of the study assessments section, clarification of SAP development timelines, and updated references to the recently finalized NIH Policy for Data Management and Sharing Policy.

CTN Trial Progress

GraphRandomizations for Active Studies as of the November 15 Trial Progress Report.

CTN-0080 - Enrolled 140

CTN-0096 - Enrolled 36

CTN-0098 - Enrolled 187

CTN-0099 - Enrolled 1742

Discontinuation -
Enrolled 208
Retention -
Enrolled 956

CTN-0101 - Enrolled 202

CTN-0107 - Enrolled 150

CTN-0108 - Enrolled 113

CTN-0109 - Enrolled 75

CTN-0110 - Enrolled 18

CTN-0116 - Enrolled 141

CTN-0126 - Enrolled 13

This project is supported by a grant from the National Institute on Drug Abuse to the University of Washington Additions, Drug & Alcohol Institute, but the information on this site has not been reviewed by NIDA and does not necessarily reflect the views of the Institute.

· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·

Submitting a Poster for CPDD 2024? Send to the PC by Dec. 1!

CTN snowflake logoCPDD is currently accepting poster abstracts for its June 2024 annual conference, with a deadline of December 29, 2023.

CPDD poster abstracts require Publications Committee (PC) review and approval prior to CPDD submission. PC reviews these poster submissions quickly usually within two weeks. Many reviewers are out of the office the holiday week of Monday, December 25 – Friday, December 29.

Please send your poster abstracts for PC review by December 1 to provide adequate time for PC review. Posters should be submitted to Jack Blaine (jblaine@nida.nih.gov) and Susan Sonne (sonnesc@musc.edu).

Don't forget to also submit your presentation slides and/or posters to the CTN Dissemination Library (as long as they don't contain unpublished data)! These create an important record of the work being done in the network and we would love to include them! Send posters/presentation slides from any event where you've presented CTN research to us at ctnlib@uw.edu.

· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·

News from the Nodes

Appalachian Node logoAppalachian Node

  • Dr. Erin Winstanley started as faculty at the University of Pittsburgh in November

  • WVU (Chestnut Ridge) celebrated it’s 100th randomization for CTN-0100 (photo below!)

  • The Appalachian Node hosted it’s annual meeting from October 25-26, 2023. Day 1 attendees, including community leaders and people with lived experience from West Virginia, students, policymakers, and funders, collaborated on developing interdisciplinary approaches to CTN studies. On Day 2, Node Leadership expanded on ideas generated during Day 1 to begin a strategic plan for future Node collaborations. For photos, check out the slideshow here!

Greater Southern California Node

Greater SoCal Node logoTelehealth & Telemedicine SIG Updates

TH/TM SIG November 17th @ 8:30am PT/11:30am ET (see flyer for details)

Cynthia Campbell, PhD., and Vanessa Palzes, MPH., will present findings from their study that examined changes in addiction treatment utilization during the first 10 months of the COVID-19 pandemic among adults with drug use problems in the Kaiser Permanente Northern California healthcare system, with a focus on differences by age group, race/ethnicity, and SES.

More information about the Telehealth & Telemedicine SIG can be found on the CTN Dissemination Library’s website here.

Opioid Use in Rural Communities: A 4-Part Series Addressing Implementation and Sustainability of Medication Treatment for Opioid Use Disorder in Rural Settings

The Greater Southern California Node (GSCN) of the National Institute on Drug Abuse (NIDA) Clinical Trials Network (CTN), in partnership with the Pacific Southwest Addiction Technology Transfer Center (PSATTC), presented a 4-part training series addressing the implementation and sustainability of medications for opioid use disorder (MOUD) in rural settings in early 2023.

The series was hosted by Larissa Mooney, M.D., Professor of Clinical Psychiatry and the Director of the Addiction Psychiatry Division in the Department of Psychiatry and Biomedical Sciences at UCLA. Expert clinical researchers and clinicians in rural communities from across the U.S. shared practical knowledge and skills for improving care for patients with OUD. Please note, individuals can earn one-hour of free CMEs and CEUs for each individual course they complete (4 courses total). 

If you missed the live sessions and would like to participate in the on-demand course and get CME/CE/PSY credit, click here

  • Session 1: Hindrances and Helps in Delivering MOUD Care in Rural Areas
  • Session 2: Telemedicine and Increasing Access to MOUD Care in Rural Communities
  • Session 3: Caring for Complex Patients in Resource-Limited Rural Communities
  • Session 4: The Substance Use Disorder Workforce in Rural Communities: Challenges and Opportunities

Post Doctoral Position at UCLA

The UCLA Integrated Substance Abuse Programs (ISAP) invites applicants for a fulltime post-doctoral position in a thriving research organization with decades of experience conducting clinical research on substance use disorders (SUDs). This position is available for an individual interested in interdisciplinary research on SUD topics, emphasizing experimental clinical trials to develop and test effective treatments for SUDs.

For more information about this opportunity, please review the flyer.

Please send a cover letter, CV, and contact information for three references to:
Yih-Ing Hser, Ph.D. (yhser@mednet.ucla.edu
Larissa Mooney, M.D. (lmooney@mednet.ucla.edu


New York Node

Sarah Meyers-OhkiSarah Meyers-Ohki recently celebrated 10 years with the New York Node.  In November 2013, Sarah joined the department of psychiatry at the New York University Grossman School of Medicine as a Research Coordinator on the CTN-0051 team at Bellevue Hospital.  She is now a Senior Project Manager on CTN-0100 – as part of the lead team and managing the Bellevue site.  

Happy 10th Anniversary, Sarah!

Northeast Node

Lynn Fiellin, MD

The Northeast Node and its parent organization, the Center for Technology and Behavioral Health at Geisel School of Medicine at Dartmouth College, are pleased to welcome Lynn Fiellin, MD, as a Node Core Investigator and faculty professor of Biomedical Data Science, Medicine, and the Dartmouth Institute for Health Policy and Clinical Practice.

Dr. Fiellin joins us from the Child Study Center and the School of Public Health at Yale. She is the founding director of the play2PREVENT Lab and of Playbl, Inc. Specifically, her work focuses on developing and testing novel videogame interventions to promote health and reduce risk in youth and young adults. She has received funding from the NIH, the FDA, and the CVS Health Foundation to conduct this work. She and her team of researchers, game developers, youth and community partners have created and evaluated interactive evidence-based digital games addressing mental health, opioid misuse, smoking/vaping, and sexual health and HIV/STI prevention.

The Northeast Node is proud to add Dr. Fiellin to our Node’s Core Investigators and look forward to further opportunities to join her important work with that of the CTN.

Read the full article here.

Western States Node logoWestern States Node

The Learning for Early Careers in Addiction and Diversity (LEAD) program, a NIDA-funded science education program focused on addictions research training, is recruiting assistant professors and assistant research scientists for the Learning for Early Careers in Addiction and Diversity (LEAD) Program for the 2024-2025.

The LEAD Program provides training to early-career research scientists from racial/ethnic minoritized groups that are underrepresented in the substance use and substance use disorder research field. 

Contact Michael Shopshire, Ph.D., michael.shopshire@ucsf.edu, if you have any questions about the program or your application. The deadline to submit for the 2024-2025 cohort is November 30, 2023!


· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·

Journal coversNew in the CTN Dissemination Library

Prescription Opioid Dose Reductions and Potential Adverse Events: A Multi-Site Observational Cohort Study in Diverse US Health Systems. Metz VE, et al. Journal of General Internal Medicine 2023 (in press). CTN-0084

Nurse Care Management for Opioid Use Disorder Treatment: The PROUD Cluster Randomized Clinical Trial. Wartko PD, et al. JAMA Internal Medicine 2023:3235701 (in press). CTN-0074

Assessment of Screening Tools to Identify Substance Use Disorders Among Adolescents. Levy S, et al. JAMA Network Open 2023;6(5):e2314422.

Research Priorities for Expansion of Opioid Use Disorder Treatment in the Community Pharmacy. Jarrett JB, et al. Substance Abuse 2023;44(4):264-276.

Treatment Initiation, Substance Use Trajectories, and the Social Determinants of Health in Persons Living With HIV Seeking Medication for Opioid Use Disorder. Cook RR, et al. Substance Abuse 2023 (in press). CTN-0067

Stakeholder Perspectives on a Telemedicine Referral and Coordination Model to Expand Medication Treatment for Opioid Use Disorder in Rural Primary Care Clinics. Ober AJ, et al. Journal of Substance Use & Addiction Treatment 2024;156:209194.

Prevalence of Cannabis Use Disorder and Reasons for Use Among Adults in a US State Where Recreational Cannabis Use is Legal. Lapham GT, et al. JAMA Network Open 2023;6(8):e2328934. CTN-0077-Ot

· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·

News from the ATTC Network

NIDA logoWords Matter: Avoiding Stigmatizing Language in SUD Treatment by Scott Weiner, MD, MPH, Brigham and Women's Hospital. ATTC Messenger, November 2023.

HHS, SAMHSA Release 2022 National Survey on Drug Use and Health report. Includes a set of easy-to-understand companion infographics.

ATTC Network: Celebrating 30 Years of Empowering Professionals by Greg Grisolano. NIATx/ATTC Service Improvement Blog, November 2023.

Upcoming Events

American Academy of Addiction Psychiatry (AAAP) Annual Meeting (San Diego, CA)
December 7-10, 2023

5th Annual NIH HEAL Initiative Scientific Meeting (Bethesda, MD)
February 7-8, 2024

American Society of Addiction Medicine (ASAM) Annual Conference (Grapevine, TX)
April 7-8, 2024

For more upcoming events, check out the Event Calendar on the CTN Dissemination Library website.



Published by the CTN Dissemination Library of the Pacific Northwest Node
Addictions, Drug & Alcohol Institute, University of Washington

This project is supported by a grant from the National Institute on Drug Abuse to the University of Washington Addictions, Drug & Alcohol Institute, but the information on this site has not been reviewed by NIDA and does not necessarily reflect the views of the Institute.

Unsubscribe | Subscribe